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ABSTRACT
GBM (glioblastoma multiforme) is a highly aggressive brain
tumour with very poor prognosis despite multi-modalities of
treatment. Furthermore, recent failure of targeted therapy
for these tumours highlights the need of appropriate rodent
models for preclinical studies. In this review, we highlight the
most commonly used rodent models (U251, U86, GL261, C6,
9L and CNS-1) with a focus on the pathological and genetic
similarities to the human disease. We end with a
comprehensive review of the CNS-1 rodent model.
Key words: U251, U87, GL261, C6, 9L, CNS-1.
INTRODUCTION
GBM (glioblastoma multiforme) is the most common and
aggressive primary brain tumour, with an extremely poor
prognosis and very few therapeutic advances in the last decade
(Wen and Kesari, 2008). Patients have an average survival of
1–2 years after diagnosis with current available treatments
(Wen and Kesari, 2008). Recently, research has advanced our
understanding of the genetics and molecular pathology of the
disease and has identified several therapeutic targets, such as
inhibitors of VEGF (vascular endothelial growth factor) and
EGFR (endothelial growth factor receptor) (Van Meir et al.,
2010). Unfortunately, these targeted therapies have not shown
success in clinical trials, despite strong preclinical data (Furnari
et al., 2007; Krakstad and Chekenya, 2010; Van Meir et al.,
2010). Although these factors developed for targeted therapy
(e.g. VEGF and EGFR) are known to be overexpressed in GBM,
the failure of successful clinical outcomes reveals the complex
nature of the disease. The dichotomy between what should be
successful therapeutic targets and the ineffectiveness of drugs
directed towards them underscores the critical importance
of appropriate and predictive rodent models in the study of
innovative therapies for the treatment of gliomas. As
researchers begin to better understand the complex inter-
action between glioma cells and their CNS (central nervous
system)/immune microenvironment, a shift away from xeno-
graft tumour models towards non-immunogenic models is
now at the forefront of GBM research. This review will first
briefly discuss the most commonly used rodent models of
GBM, with a focus on the potential for these models to
recapitulate the human brain neoplasm on genetic, imaging,
pathophysiology and therapeutic levels. Finally, we present a




The U251 malignant glioma cell line was originally established
from a 75-year-old male with GBM by Ponten and others
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(Ponten, 1975; Houchens et al., 1983). This GBM cell line is
known tomimic the salient features of human GBM and as such
has received significant attention over the last four decades in
xenogeneic mouse models of cancer (Houchens et al., 1983;
Harada et al., 1994; Husain et al., 1998; Candolfi et al., 2007;
Radaelli et al., 2009). The U251 cell line has been used both in
subcutaneous and intracranial mouse models (Camphausen
et al., 2005). For example, the intracranial model involves
injections of 16105–16106 of U251 cells suspended in 5–25
ml (Houchens et al., 1983; Candolfi et al., 2007), approx. 2 mm
anterior to the bregma and 2 mm to the left (or right) of the
midline inserted 2–3 mm deep into the striatum of the brain
(Houchens et al., 1983; Valdes et al., 2010) of athymic nude
mice.
Pathology
This intracranial mouse model recapitulates most of the key
salient features of GBMs at the histopathological level
(Candolfi et al., 2007; Wen and Kesari, 2008; Radaelli et al.,
2009). Under H/E (haematoxylin/eosin) staining, U251 cells
show an infiltrative pattern of invasion into normal brain
parenchyma, significant foci of palisading necrosis, a tortuous
pattern of microvascular proliferation, hypertrophic endothe-
lium, cellular pleomorphism, giant multinucleated cells, atypia
including mitotic figures and irregular nucleoli, and foci of
oedema and haemorrhage (Candolfi et al., 2007; Radaelli et al.,
2009). While the invasion pattern is not strongly diffused
along white matter tracks, it does present perivascular
satellitosis and subpial spread. However, this rodent model
lacks perineuronal satellitosis and invasion along white matter
tracks. Immunohistochemical analysis of U251 xenografts
shows striking similarities to GBMs, with neoplastic cells
positive for GFAP (glial fibrillary acidic protein), vimentin and
S100B staining (Kleihues and Cavenee, 2000; Brat and Van
Meir, 2004; Homma et al., 2006; Radaelli et al., 2009). Tumour
cells also show high levels of cellular proliferation, with over
50% of tumour cells staining positive for Ki-67. At regions of
pseudo-palisading necrosis and perinecrotic areas, these
tumours display positive caspase 3 and HIF1-a (hypoxia-
inducible factor-1a) staining (Radaelli et al., 2009). Finally, in
recent years, interest has arisen regarding tumour stem cells
(Van Meir et al., 2010). This tumour model contains a CD133+
subpopulation of cells able to form neurosphere aggregates
with self-propagating potential (Qiang et al., 2009).
Genetics
The U251 xenograft model also displays similarities at the
genetic level to human GBM (Louis, 1994; Louis et al., 2001;
Furnari et al., 2007; Krakstad and Chekenya, 2010; Van Meir
et al., 2010), with the identification of non-functional mutant
tumour suppressor p53 (Radaelli et al., 2009) as well as mu-
tant PTEN (phosphatase and tensin homologue deleted on
chromosome 10). Deletions of p14ARF and p16, two cell cycle
suppressor genes whose function is as critical negative
regulators of Cdks (cyclin-dependent kinases), and whose
deletion leads to loss of activity of the retinoblastoma protein
(Furnari et al., 2007), are observed in U251 (Fueyo et al., 1996;
Ishii et al., 1999) (Table 2). The PI3K (phosphoinositide 3-kinase)/
Akt (also known as protein kinase B) pathway shows up-
regulation in U251 as a result of high Akt expression. This has
been shown to be a contributing factor in the increased survival,
proliferation, migration, angiogenesis and resistance to apop-
tosis observed in GBM (Koul et al., 2006; Furnari et al., 2007;
Radaelli et al., 2009). A study by Camphausen et al. (2005).
reported gene expression profile differences between subcutan-
eous and intracranial tumour models, noting the importance of
different in vivo growth conditions and the role of the
microenvironment in U251.
Summary
In summary, U251 recapitulates the salient histological and
immunohistochemical features of human GBM. In addition,
a number of genetic alterations show similarities to human
GBM, including alterations in key tumour suppressors and
oncogenic pathways. Further, MRI (magnetic resonance
imaging) features of the U251 mouse model correlate with
human GBM, including a necrotic centre, poorly demarcated,
infiltrative tumour borders and an enhanced rim on T2-
weighted imaging; on post-contrast T1-weighted images an
intense rim is observed similar to human GBM (Radaelli et al.,
2009). Brain volume is a limiting factor for imaging, as more
powerful, expensive magnets are required to achieve propor-
tionately better imaging of anatomical structures. Equivalent
images of whole mice brains compared with rat brains require
a more expensive, powerful MRI magnet to obtain similar
resolution of anatomical structures, which may be unavailable
to the investigator. Finally, this xenogeneic mouse model is
criticized for not reproducing the tumour–host immune
response. Future work requires full genome sequencing of
U251 and comparison with GBM.
U87 GLIOMA MODEL
General protocol
The U87 GBM model was originally established by Ponten
and colleagues from a female with GBM (Ponten, 1975). This
tumour model shows significant dissimilarities when compared
with the U251 model and human GBM, but has nevertheless
received significant attention, especially for assessing tumour
angiogenesis and anti-angiogenic therapies (Candolfi et al.,
2007; de Vries et al., 2009; Radaelli et al., 2009). Similar to the
U251 model, this model shows significant gene expression
profile differences between differing in vivo growth conditions
(e.g. subcutaneous and intracranial) (Camphausen et al., 2005).
Similar to the U251 murine model, the intracranial model
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involves concentrations of 16105–16106 of U87 cells sus-
pended in 5–10 ml, and injections at approx. 1 mm anterior
and 3 mm lateral to the bregma inserted 3–4 mm deep into the
brain (Roberts et al., 1998; Rubin et al., 2003; Moore et al.,
2004; Candolfi et al., 2007) or right striatum (Roberts
et al., 1998) of athymic nude mice.
Pathology
The U87 model displays key dissimilarities to the U251 model and
human GBM at the histopathological level (Kleihues and
Cavenee, 2000; Brat and Van Meir, 2004; Homma et al., 2006;
Rong et al., 2006; Candolfi et al., 2007; de Vries et al., 2009;
Radaelli et al., 2009). U87 tumours are highly cellular with atypia
such as mitotic figures and irregular nucleoli, and profuse
neovascularization (Candolfi et al., 2007). Unlike GBM, these
tumours show a non-diffusely infiltrative growth pattern, with a
well-demarcated tumour mass surrounded by reactive astrocytes
(de Vries et al., 2009; Radaelli et al., 2009). Tumour vasculature
shows significantly more homogeneous and leaky vessels, which
means greater access by systemic drugs, in contrast with GBM
(de Vries et al., 2009). Further, necrotic foci are rare in number
with features differing from GBM, including no pseudo-
palisading patterns and neutrophil infiltration (Candolfi et al.,
2007; Radaelli et al., 2009). U87 tumour cells stain negative for
GFAP and S100, but positive for vimentin and over 40% positive
nuclei for Ki-67. GFAP positive staining is only observed at the
reactive astrocyte border surrounding the well-demarcated
tumour mass (Candolfi et al., 2007; Radaelli et al., 2009). The
necrotic foci also display areas of positive caspase 3 and HIF1-a
staining (Radaelli et al., 2009). Finally, similar to the U251 model,
U87 tumours show a CD133+ subpopulation of cells able to form
neurosphere aggregates with self-propagating potential, of
interest to the tumour stem cell community (Qiang et al., 2009).
Genetics
U87 cells show several similarities as well as some key diffe-
rences to human GBM (Louis, 1994; Louis et al., 2001; Furnari
et al., 2007; Krakstad and Chekenya, 2010; Van Meir et al.,
2010). Unlike the U251 model, U87 demonstrates a wild-type
tumour suppressor p53 (Radaelli et al., 2009). U87 shows a
mutant PTEN, deletion of p14ARF and p16 (Fueyo et al., 1996;
Ishii et al., 1999), and PI3K/Akt pathway up-regulation as a
result of high Akt expression (Koul et al., 2006; Furnari et al.,
2007; Radaelli et al., 2009) (Table 2). The study by Camphausen
et al. (2005) mentioned above found significant differences
between U87 and U251 when grown in vitro or under sub-
cutaneous conditions, but found that both lines displayed
similar gene expression patterns when grown intracranially. A
recent whole genome sequencing of U87 was performed (Clark
et al., 2010). This study examined the various mutations, homo/
heterozygous deletions and intra/interchromosomal events,
which included over 140 genes affected by complete deletion
(e.g. CDKN2A) and common mutations found in gliomas (e.g.
PTEN).
Summary
Unlike the U251 xenogeneic model, U87 shows significantly
less similarity to human GBM and as such caution must be
used when extrapolating conclusions from studies using the
U87 cell line. Further, a key feature of human GBM, which
significantly contributes to its resistance to therapy and high
recurrence rate, is the diffusely invasive infiltration pattern
into normal brain parenchyma of tumour cells (Louis et al.,
2001). In the U87 model, tumours show clear demarcation
from normal parenchyma without the diffusely infiltrative
pattern of GBM and lack GFAP or S100B immune staining. At
the genetic level, there are key differences and similarities to
human GBM, which include a wild-type p53 and aberrant
PI3K/Akt respectively. Finally, MRI features of the U87 mouse
model including a homogeneous and enhanced, well-
demarcated tumour nodule on T2-weighted imaging, which
does not correlate well with GBM (Radaelli et al., 2009).
Furthermore, investigators should be aware that the xeno-
graft models can incorporate host (non-human) glycolipids,
possibly altering the biochemical and immunogenic prop-
erties of the model (Ecsedy et al., 1999). Overall, this tumour
model has been used to test anti-angiogenic therapies, but
limitations of extrapolating conclusions from this model
system include the aforementioned dissimilarities to human
GBM, as well as the usual concerns with xenogeneic models
and limitations with MRI of small rodents.
GL261 GLIOMA MODEL
General protocol
GL261 is a syngeneic mouse model of GBM in C57BL/6 mice
that do not require a deficient immune system. As a result
this model may mimic more closely the growth and immune
response of human GBM. Seligman and Shear originally
developed the model in 1939 through intracranial implanta-
tion of 20 methylcholanthrene pellets into mice brains
(Seligman and Shear, 1939; Newcomb and Zagzag, 2009). In
general, 16105 GL261 tumour cells are injected in a volume of
2–4 ml, 2 mm from the sagittal suture at a depth of 3 mm (Zhu
et al., 2010). Several advances in experimental immunotherapy
for GBM have been achieved using this model given this is an
immune competent model and there are a vast number of
antibodies and immune markers available for mice (Maes and
Van Gool, 2011).
Pathology
Early descriptions of GL261 cells describe this tumour as
displaying ependymoblastoma characteristics. Recent work
further describes poorly differentiated cells with morphology
similar to human GBM cells (Shapiro et al., 1970; Zagzag
et al., 2000). A key feature of this model is the diffusely
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infiltrating and invasive characteristics of GL261 cells into
normal brain. Histopathological examination demonstrates
individual cell invasion several millimetres away from the
tumour margin (Zagzag et al., 2003; Newcomb and Zagzag,
2009). These invasive cells display several of the ’secondary
structures of Scherer’: (i) perineuronal satellitosis, (ii) perivas-
cular satellitosis, (iii) subpial spread and (iv) invasion along
the white matter tracts (Burger et al., 2002). Furthermore,
GL261 tumour cells express CXCR4 (CXC chemokine receptor
4), which has been linked to the invasive and migratory
properties of GBM (Zagzag et al., 2008). GL261 also displays
endothelial thickening based on increased CD31 expression
[30]. Similar to GBM, GL261 tumours have areas of pseudo-
palisading necrosis. Along with an invasive phenotype, the
GL261 mouse model shares many histopathological markers
with human GBM. GL261 tumours stain positive for GFAP and
S100 and endothelial cells stain positive for CD31 antigen
(Newcomb and Zagzag, 2009). The tumours express areas of
angiogenesis and hypoxia, which correlate with expression
of VEGF and HIF-1a (Zagzag et al., 2003). Both of these
markers have been shown to correlate with an increase in
growth and decreased survival in patients with GBM (Zagzag
et al., 2006).
Genetics
Genetically, GL261 cells share many key mutations with
human GBM. Point mutations in the K-ras oncogene and p53
tumour suppressor gene have been identified (Szatmari et al.,
2006; Candolfi et al., 2007) (Table 2). GL261 cells also
demonstrate increased activation of the PI3K pathway and
phosphorylation of Akt, a serine/threonine protein kinase,
leading to downstream signalling both in vitro and in vivo
(Choe et al., 2003; Furnari et al., 2007). The PI3K/Akt
signalling pathway is often dysregulated in human GBM
tumour cells, leading to EGFR expression, increased prolif-
eration, survival and cellular migration observed in GBM
(Choe et al., 2003; Furnari et al., 2007; Van Meir et al., 2010).
Summary
Several aspects of GL261 allow for an excellent model of
human GBM, particularly when compared with xenograft
models (U251 and U87) in immune suppressed mice. GL261
tumour cells share several important markers and mutations
with human GBM. The diffusely infiltrative property of GBM is
one of the major reasons for failure of current treatment (Wen
et al., 1990; DeAngelis, 2001; Furnari et al., 2007; Van Meir et al.,
2010), and the GL261 model recapitulates this feature on micro-
scopic examination. As mentioned previously, one of the major
challenges in using a mouse model is the size of the brain,
particularly in studies that require imaging techniques like MRI.
Equivalent images of whole mice brains compared with rat
brains require a more expensive, powerful MRI magnet to obtain
similar resolution of anatomical structures, which may be un-
available to the investigator. In conclusion, when imaging is not
a limitation, GL261 is a strong model for studying GBM
therapies, particularly immune-based therapies.
C6 GLIOMA MODEL
General protocol
The C6 glioma cell line was developed in the late 1960s
in Sweet’s laboratory by repetitive administration of MNU
(methylnitrosourea) in adult Wistar–Furth rats (Benda et al.,
1968). Although originally developed in Wistar rats, C6 can be
implanted in Sprague–Dawley and Long–Evans rats without
rejection (Nagano et al., 1993; Whittle et al., 1998). Tumour
cells are usually implanted into the fronto-parietal lobe at
16105 cells in 5 ml, with variable rates of tumour take (Parsa
et al., 2000; Branle et al., 2002). This tumour can also be
implanted on the right flank for easier measurements in
growth studies and associated limitations in extrapolating
from subcutaneous studies.
Pathology
C6 glioma cells share several general histopathological and
specific tumour markers with human GBM. C6 glioma tumours
demonstrate regions of focal invasion into brain tissue when
implanted in Wistar rats, similar to the diffuse infiltrating
pattern seen in GBM (Chicoine and Silbergeld, 1995) At the
cellular level, C6 tumours do display areas of necrosis, nuclear
polymorphism and high mitotic rates (Auer et al., 1981). In
terms of histopathological markers, C6 cells express S100B
protein, but do not express GFAP, and variable levels of
vimentin (Pfeiffer et al., 1970; Whittle et al., 1998; Chou et al.,
2003).
Genetics
The genetics of the C6 cell line offer further comparison with
human GBM. A common tumour suppressor gene, p16, is
known to have a high mutation rate in GBM and mutations in
the p16/CDKN2A/NK4A locus are frequent occurrences in C6
tumour cells (Ueki et al., 1996; Ishii et al., 1999; Schlegel
et al., 1999; Furnari et al., 2007) (Table 2). The tumour
suppressor, p53 is one of the most frequently mutated genes
in human GBM, and the C6 cell line differs from humans in
their expression of the tumour suppressor protein p53 with
a wild-type p53 along with minimal PTEN expression (Asai
et al., 1994).
Summary
A clear advantage in using the C6 glioma model is the
extensive characterization and the literature produced using
this model, including genetic analysis (Grobben et al., 2002).
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However, the immunogenicity of this model is an important
factor that must be considered even when studying non-
immune based therapies. When placed in a Sprague–Dawley
or Long–Evans rats, the tumour loses its invasive character-
istics and grows in an encapsulated manner, no longer
resembling the diffusely infiltrative nature of GBM (San-Galli
et al., 1989). For example, Parsa et al. (2000) demonstrated
strong antibody responses to C6 even when grown in Wistar
rats. In conclusion, any therapeutic development and testing
in this model must be interpreted with caution.
9L GLIOMA MODEL
General protocol
The 9L glioma model is historically one of the most widely
used glioma tumour models. It has been extensively used to
study chemotherapy and radiation effects (Henderson et al.,
1981; Wen et al., 1990; Kimler et al., 1992; Kruse et al., 1993).
Recently, it has also been used to study tumour stem cells
(Ghods et al., 2007). The 9L gliosarcoma cell line was
originally developed by Brenda, Schmidek and colleagues
in the 1970s through repetitive administration of MNU in
Fischer 344 rats (Benda et al., 1971; Schmidek et al., 1971).
Most research in this cell line has been conducted with the
syngeneic Fischer rats; however, it has also been character-
ized in allogenic Wister rats (Stojiljkovic et al., 2003). Tumour
cells are usually injected into the striatum at a volume of
16105 cells in 5 ml of cell suspension, showing high rates of
tumour take after implantation (Stojiljkovic et al., 2003).
Pathology
It is important to note that 9L tumour cells have a
sarcomatous appearance under histopathological examina-
tion, differentiating this model from other glioma models
(Barth, 1998). 9L cells share some histological similarities with
GBM tumour cells. For example, they are S100b-positive.
However, they do not express GFAP and do not show the
typical GBM pattern of diffusely invasive cells (Benda et al.,
1971). In Wistar rats, tumours are infiltrated by macrophages
and microglia (ED1 positive) and CD4
+/CD8+ T-cells after
approx. 2 weeks of growth (Stojiljkovic et al., 2003). Despite
evidence of a T-cell immunological response, tumour growth
is not inhibited in this model when compared with other
rodent models with immune responses.
Genetics
Similar to human GBM cells, 9L cells have a mutant p53 gene
(Asai et al., 1994). They also over express EGFR (epithelial
growth factor receptor), which has been extensively studied
as a therapeutic target in human GBM (Sibenaller et al., 2005;
Lo, 2010). 9L differs from humans in their expression of p16,
FGFR-1 (fibroblast growth factor receptor-1) and PDGFRb
(platelet-derived growth factor receptor b; Sibenaller et al.,
2005), all of which are mutated or highly expressed in GBM,
but not in 9L. The 9L tumour cells also fail to express other
commonly mutated tumour suppressor genes such as PTEN.
Summary
Despite the wide use of the 9L glioma model, it is important to
note the significant differences when compared with human
GBM. Currently, the WHO (World Health Organization) classifies
gliosarcoma as a subset of grade IV gliomas (Louis et al., 2001).
However, careful consideration should be implemented when
using a gliosarcoma model as a general model for GBM. Recent
review of the literature has identified unique histological and
genetic characteristics of gliosarcoma compared with GBM
(Han et al., 2010). Some of these differences include infre-
quency of EGFR mutations and temporal lobe predilection, an
implication that this subset of tumours may respond uniquely
to various therapies (Han et al., 2010). 9L is considered an
immunogenic tumour, since it is possible to immunize synge-
neic rats with irradiated 9L tumour cells (Denlinger et al., 1975).
Furthermore, the circumscribed growth pattern serves as a poor
model to study the invasive properties of gliomas.
CNS-1 GLIOMA MODEL
General protocol
In 1990, Dr Michael C. Molleston, working in the laboratory
of one of the authors (W.F.H.) sought to develop a syngeneic
astrocytoma model. Each week for 36 weeks, he intravenously
injected young rats with 5.0 mg/kg of MNU. Approx. 7
months after the start of treatment, rats began to die of
tumours. One rat was found moribund and it was possible to
obtain an MRI scan (Figure 1a). The study showed a well-
developed neoplasm in the basal ganglia. From this tumour,
the CNS-1 tumour line was established. CNS-1 tumour cells
are usually injected into the striatum at a volume of 16105
cells in 5 ml of cell suspension. Original studies with this cell
line indicate median survival time of 30 days with high
tumour take (Kruse et al., 1994).
Pathology
At the time that the CNS-1 cell line was developed, the
currently available GBM models failed to recapitulate many
of the key characteristics of tumour growth in vivo. CNS-1
tumour cells were unique in their ability to express several
glioma markers. These include positive staining for GFAP,
S100Bb, vimentin, RAR-a (retinoic acid receptor a), intracel-
lular adhesion molecule-1 and neuron-specific enolase (Kruse
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et al., 1994) (Table 1). A key feature of the CNS-1 model is
also the diffusely infiltrative and invasive pattern of growth
in vivo. Unlike the 9L glioma model, CNS-1 cells demonstrate
perivascular spread and individual tumour cell infiltration
into normal parenchyma (Kruse et al., 1994). CNS-1 cells
demonstrate periventricular spread and liptomeningeal
spread (Kruse et al., 1994).
The tumour microenvironment is known to promote tumour
cell growth and invasion. This should be taken into consi-
deration when choosing an appropriate animal model for
therapeutic studies. Several immunological studies have been
conducted with the CNS-1 model to elucidate the micro-
environment’s role in tumour growth (Owens et al., 1998;
Regina et al., 2003; Demeule et al., 2004). In the presence of a
brain tumour, endothelial cells may undergo phenotypic and
functional changes, which result in promotion of tumour
growth (Demeule et al., 2004). In the presence of CNS-1
tumour, endothelial cells undergo hyperplasia and display a
pseudo-palisading pattern accompanying necrosis (Kerbel,
2008), both of which are indications of increased angiogenesis
mimicking human GBM (Beranek, 2002).
The angiogenic nature of GBM is well established and
has historically been a target for therapeutic development
(Kerbel, 2008). Endothelial cells are also involved in drug
resistance across the BBB (blood-brain barrier), by helping to
prevent leakiness of the BBB. For example, P-glycoprotein is
an efflux transporter in endothelial cells, which prevents
significant accumulation of hydrophobic drugs (van Asperen
et al., 1997). Histopathologic examination of human GBM
shows a high expression of P-glycoprotein, possibly offering
an explanation for clinical drug resistance in these tumours
(Sawada et al., 1999).
In addition to endothelial cells, microglia and macrophages
also support tumour growth and invasion. In human GBM,
these cells accounts for as much as 10–34% of the tumour
mass (Roggendorf et al., 1996). There is a strong positive corre-
lation between the number of macrophages and microglia and
the grade of tumour (Kielian et al., 2002). Similar to human
GBM, CNS-1 brain tumours demonstrate infiltration of macro-
phages and microglia, constituting a major proportion of the
tumour cell mass (Kielian et al., 2002). As a result, the CNS-1
model has been used to investigate the relationship between
tumour cells, microglia and macrophages. MCP-1 (monocyte
chemoattractant protein-1) was identified as a chemoattrac-
tant secreted by tumour cells, promoting the migration of
microglia and macrophages to the tumour site (Kielian et al.,
2002). Several tumour-promoting cytokines have been
detected at the tumour site in vivo, but not by CNS-1 cells
in vitro, further supporting the role of immune cells in the
tumour microenvironment (Kielian et al., 2002). These
Figure 1 Characteristics of the CNS-1 rat glioma model
(a) MRI of the original tumour in which the CNS-1 tumour cell line was derived. (b) T1-weighted MRI of 16105 CNS-1 cells in Lewis
rat on day 15. Tumour is highlighted in green. To the right is a 3D reconstruction of the tumour using Mimics Software (Materialise,
Leuven, Belgium) by summing the number of voxels that exceeded the intensity threshold in each plane on the T1-weighted
subtraction images and multiplying by the appropriate spatial scaling factor (0.35 mm60.35 mm61.00 mm per voxel). (c) GFAP
staining of the first cell line of CNS-1. (d) An H/E staining of infiltrating tumour cells into normal parenchyma of a Lewis rat brain
(scale bar indicates 100 mm).
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cytokines include IL-1a, IL-1b, IL-10, TNFa (tumour necrosis
factor a), TNFb and IFNc (interferon-c; Kielian et al., 2002).
As previously mentioned, the CNS-1 model may be used to
study the invasive properties of tumour cells. Plasminogen
activators are traditionally involved in the breakdown of blood
clots. However, they are also highly expressed in GBM and in-
volved in degradation of surrounding tissue, promoting tumour
invasion (Demeule et al., 2004). Endothelial cells surrounding
CNS-1 tumours up-regulate urokinase plasminogen activators
[tPA (tissue plasminogen activator), PA (plasminogen activator),
PAI-1 (plasminogen-activator inhibitor) and uPAR (urokinase-
type plasminogen activator receptor)] (Demeule et al., 2004).
MMPs (matrix metalloproteinases) are another class of enzymes
involved in degradation and tumour invasion. MMPs have been
implicated as a crucial target in GBM cell invasion and as a
result have been the focus for therapeutic development
(Furnari et al., 2007). CNS-1 cells express MMP-2, but do not
express MMP-9. However, expression of MMP-9 has been
detected in endothelial cells and microglia found within the
tumour microenvironment (Regina et al., 2003).
Unlike some of the other tumour models, the genetics of
CNS-1 have not been extensively studied. Here, we briefly
discuss the molecular work that has been undertaken and
molecular players identified in the CNS-1 cell line. The
karyotype of CNS-1 cells demonstrates one or more trisomies
often of chromosomes 11 and 13 (Kruse et al., 1994). In terms
of protein expression, CNS-1 cells were used to correlate
decreased activity of L-isoaspartyl methyltransferase (a
repair enzyme) in gliomas (Lapointe et al., 2005). Most of
the research surrounding CNS-1 proteins has focused on its
invasive phenotype. BEHAB (brain-enriched hyaluronan-
binding) protein is a chondroitin sulfate proteoglycan found
in the ECM (extracellular matrix). BEHAB expression is
increased in gliomas and has been associated with glioma
cell migration and proliferation (Jaworski et al., 1996).
BEHAB/brevin cDNA was transfected into CNS-1 cells and
implanted into Lewis rats. Tumours with BEHAB/brevin cDNA
had a decreased survival and increased invasion and vascula-
ture on histology (Nutt et al., 2001). The CNS-1 rodent model
was then used to identify ADAMTS5 (a disintegrin and metal-
loproteinase with thrombospondin motifs 5) as the MMP
required for proteolytic cleavage of BAHAB/brevin (Viapiano
et al., 2008). Another protein characterized in CNS-1 involved
in migration and invasion is the NCAM (neural cell adhesion
molecule; Owens et al., 1998). CNS-1 cells transfected with
NCAM demonstrated increased invasion in vitro. However,
under in vivo conditions, NCAM increases local infiltration
but decreases long-range invasion and migration. These
results help to differentiate the mechanisms and signalling
involved in glioma invasion. Many of the therapeutic studies
investigated using the CNS-1 cell model involve gene therapy.
For a summary of therapeutic studies in the CNS-1, we refer
readers to Table 3.
Summary
The CNS-1 rodent model shares several key features with
human GBM, including histological markers and growth
pattern. The role of the immune environment has also been
extensively investigated in this model. Although there has
Table 1 Characteristic histological markers and growth of tumour cells in GBM rodent models
Expression of histological markers and growth characteristics are indicated by (+), while failure of expression is indicated by (2).
Rodent and model Markers Growth
GFAP S100b Vimentin Invasive Immunogenic
Mouse
U251 + + + 2 +
U87 2 2 + 2 +
GL261 + + +/2 + 2
Rat
C6 2 + N/A +/2 +
9L 2 + N/A 2 +
CNS-1 + + + + 2
Table 2 Genetic characteristics of rodent GBM models
The presence of a genetic mutation is indicated by (+), while overexpression is indicated by (++).
Genetic mutation or overexpression
Rodent and model p14 p16 PTEN p53 kRAS EGFR
Mouse
U251 + + + + + ++
U87 + + + 2 + 2
GL261 + + + + + ++
Rat
C6 2 + 2 2 N/A ++
9L 2 2 2 + N/A ++
CNS-1 N/A N/A N/A N/A N/A N/A
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been some work, an extensive understanding of the genetics
in CNS-1 cells is lacking. Despite this, CNS-1 cells share
several histological features and diffuse growth pattern with
human GBM and is one of the few models that also
recapitulates the tumour microenvironment.
CONCLUSION
Rodent models of GBM have been available for decades;
however, very few new therapies have successfully translated
into the clinic during this time (Louis et al., 2001). The extent
to which these models recapitulate the human disease
remains debatable. GBM is one of the most challenging
tumours to treat with approx. 1 year median survival
following diagnosis. Despite aggressive surgery, chemother-
apy and radiation treatments, the tumours virtually always
relapse (Van Meir et al., 2010). An ideal model should
recapitulate the key histopathological, genetic and imaging
features encountered in GBM’s aggressive growth as well as
being a reproducible, reliable model.
As ongoing research continues to shed light on the genetic
and cellular mechanisms involved in GBM, these new
advances must be taken into consideration when choosing
an appropriate model. Currently available rodent models can
be classified into spontaneous oncogenesis, allograft or
xenograft. For this review, we focused on engrafted models.
However, we direct the reader to Sonabend et al. (2007) for a
more extensive review on the several GBM genetic mouse
models available. Also, our review provides only a general
overview on the histopathological comparison of the rodent
tumour cells to human GBM, since this has been reported
previously (Radaelli et al., 2009).
We summarize herein some of the most commonly used
rodent models of GBM with a focus on the CNS-1 rat model.
Two of the most commonly used mouse models presented
herein, U251 and U87 are xenograft models used in athymic
nude mice. Comparing these cell lines, U251 is histologically
most similar to human GBM. While these models enable the
use of human GBM tumour cell lines, they are in an immune-
compromised rodent, which does not allow for adequate
study of the tumour–CNS/immune microenvironment. The
mouse GL261 model, however, is a syngeneic model in C57BL/
6 mice. This murine model demonstrates several of the critical
GBM characteristics such as secondary structures of Scherer
and tumour suppressor gene mutations. It is important to
mention a more recent mouse model of GBM that has not
been extensively reported in the literature but does share
several key phenotypes with GBM. The VM-M3 model is
derived from a spontaneous astrocytoma in the VM/dK strain
of mice. These tumour cells are highly infiltrative, dem-
onstrating all four secondary structures of Scherer and
expression of CXCR4 (Shelton et al., 2010). Since this rodent
model was only recently introduced, there are no extensive
data pertaining to its histological and genetic markers. It is
known that they do not express GFAP. However, this presents
yet another promising model for the study of glioma invasion.
Both 9L and C6 in rats (when grown in Sprague–Dawley
rats) as well as U87 in mice demonstrate well-circumscribed
tumour growth patterns in vivo. C6 can grow invasively in
Wistar–Furth rats. However, rats do produce strong immune
responses to C6 tumour cells. The CNS-1, U251 and GL261
models, in comparison, share several histological surface
markers with human GBM and grow in a very similar pattern
(i.e. diffusely infiltrative) in vivo. An advantage of using a rat
rodent model compared with mouse is the ease in performing
imaging studies in a rat due to its larger size.
Advancements have been made in the understanding of
how GBM tumour cells invade and interact with their im-
mune environment. As we move towards developing new
therapeutics and testing in animal models, researchers must
ensure rodent models are incorporating our new under-
standings of GBM. Failure to do this will only elicit further
therapeutic developments that will fail in clinical trials. Both
the CNS-1 model in rats and the GL261 model in mice have
been used to investigate the role of the tumour micro-
environment. This review presented the most common rodent
glioma models, highlighting their differences when compared
with the human disease. In addition, we presented the first
comprehensive review of the CNS-1 glioma model. An
understanding of how glioma models recapitulate the disease
will enable scientists to choose the best model for preclinical
studies, hopefully translating to more successful clinical trials
in the future.
Table 3 Therapeutic studies conducted in the CNS-1 GBM rodent model
Category Year Therapy References
Virus 2004, 2008
and 2010
Adenovirus vectors encoding Flt3L adenovirus
vector expressing HSV1-TK (Herpes simplex virus
type I thymidine kinase) and FLT3L
(Ali et al., 2004; King et al.,
2008; Puntel et al., 2010)
Vectors 2004 Block TGFb with transfected decorin gene (Biglari et al., 2004)
Gene therapy 2000 and 2003 CpG oligodeoxynucleotides blockage of IGF-1
(insulin-like growth factor 1) with antisense
and triple helix IGF-1 expression
(Carpentier et al., 2000;
Trojan et al., 2003)
Imaging 2002 and 2007 BOLD imaging of O2 detection PPIX fluorescence (Dunn et al., 2002; Bisland
et al., 2007)
Small molecule 2011 Propentofylline VL Jacobs, RP Landry, Y Liu,
EA Romero-Sandoval and SA
De Leo, unpublished work
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